top-home.jpg

Starpharma’s Priostar® Glyphosate Patent Allowed in China

Appendix 4C - Quarterly Cashflow Statement

Starpharma raises $3.5M through SPP following $18M Placement

VivaGel® condom now available in Australian stores

DEP™ docetaxel shows intended longer duration and increased exposure

Sexual Health Drug Delivery Agrochemicals Wider Applications
         
 

Starpharma Holdings Limited is a world leader in the development of dendrimer products for pharmaceutical, life-science and other applications.

Starpharma’s lead products based on VivaGel® (SPL7013, astodrimer sodium) are for the management of bacterial vaginosis (BV), and for prevention of transmission of sexually transmitted infections (STIs), including HIV and genital herpes.  The VivaGel® condom has been licensed to Ansell and Okamoto.  A VivaGel® condom has obtained conformity assessment certification from the Australian Therapeutic Goods Administration (TGA).  Regulatory certification (marketing approval) has also been granted for marketing by Okamoto of the VivaGel® condom in Japan.

 

 

In the wider pharmaceutical and life science fields, Starpharma has specific programs in dendrimer drug delivery, including drug targeting, drug solubilisation, diagnostics and pharmaceutical excipients.

More broadly, Starpharma is exploring dendrimer opportunities in agrochemicals, cosmetics and materials science with applications as diverse as paints, coatings, adhesives, and water remediation.

 
         

invester-center.jpg

Code Last $+/-
SPL 0.510 0.000

Data provided by asx.com.au. Prices are delayed by at least 20 minutes.

© Starpharma Holdings Limited 2014